Safety of biological agents in paediatric rheumatic diseases: A real-life multicenter retrospective study using the JIRcohorte database - 01/05/19
, Jean-Christophe Lega a, c, Behrouz Kassai a, d, Carine Wouters e, f, Anuela Kondi g, Elvira Cannizzaro h, Andreas Woerner i, Aurelie Chausset j, Samuel Roethlisberger k, Cyril Jeanneret k, Florence Aeschlimann h, Salma Malik d, Agnès Duquesne b, Daniela Kaiser l, Laetitia Higel m, Anne Maes e, f, Gerald Berthet n, Veronique Hentgen o, Isabelle Kone-Paut g, Alexandre Belot b, Michael Hofer iBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 8 |
| Iconographies | 0 |
| Vidéos | 0 |
| Autres | 0 |
Highlights |
• | The overall safety of biological agents (BAs) in paediatric rheumatology practice is acceptable in real life. |
• | The combination of immunosuppressive drugs with BAs may contribute to side effects and a cautious follow-up should be considered in this setting. |
• | Varicella-zoster virus represents the main (preventable) infection under treatment. |
Abstract |
Objective |
To analyse and report the incidence of side effects of biological agents in paediatric patients with inflammatory diseases using of real-life follow-up cohort.
Methods |
In this international, observational, retrospective, multicentre study of children treated by biological agents and followed in the Juvenile Inflammatory Rheumatism (JIR) cohort (JIRcohorte) network, a Kaplan–Meier method was used to estimate the occurrence of adverse events. A Cox model was constructed to identify independent predictors of adverse events.
Results |
Overall 813 patients totalling 3439 patients–year (PY) of biological agents were included. The main diagnosis was juvenile idiopathic arthritis (84%). A total of 222 patients (27.3%) had 419 adverse events, representing an incidence rate of 12.2 per 100 PY 95% CI [11.0; 13.4]. The overall incidence rate of serious adverse events was 3.9 per 100 PY 95% CI [3.2; 4.6]. Tocilizumab and infliximab were significantly associated with adverse events and canakinumab with serious adverse events. Univariate and multivariable analysis of adverse events and serious adverse events indicated that patients under biological agents with concomitant immunosuppressive drugs (excluding methotrexate) suffered from more of these events.
Conclusion |
This study suggests an overall an acceptable safety of biologic agents in children with inflammatory rheumatic diseases treated with biological agents. However, the concomitant prescription of immunosuppressive drugs with biological agents represents a substantial risk of adverse events.
Le texte complet de cet article est disponible en PDF.Keywords : Biological agents, Paediatric rheumatology, Juvenile idiopathic arthritis, Adverse events, Serious adverse events, JIRcohorte
Plan
Vol 86 - N° 3
P. 343-350 - mai 2019 Retour au numéro
Article précédent
- Serum retinol-binding protein 4 is associated with insulin resistance in patients with early and untreated rheumatoid arthritis
- Yanlin Wei, Nannan Xia, Weifeng Zhang, Jiashu Huang, Zhijuan Ren, Lijuan Zhu, Zhenshan Zhang, Lei Yang
- Adverse consequences of low-dose methotrexate medication errors: data from French poison control and pharmacovigilance centers
- Thierry Vial, Anne Marie Patat, David Boels, Delphine Castellan, Antoine Villa, Hélène Theophile, Romain Torrents, Behrouz Kassai
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?